The Food and Drug Administration (FDA) has further expanded the U.S. indications of Novo Nordisk’s (NVO) popular weight loss ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

New research links two widely used diabetes drugs, semaglutide or tirzepatide, to a rare but potentially vision-threatening eye condition, raising questions about drug-specific risks and the need ...

As weight-loss drugs are gaining popularity among Indian diabetes and obesity stricken patients in India, new research highlights rare but serious eye risks linked to the blockbuster GLP-1 medications ...

GLP-1 receptor agonists like semaglutide and the dual GIP/GLP-1 agonist tirzepatide mimic naturally occurring hormones that regulate blood sugar, appetite, and digestion. GLP-1 (glucagon-like ...

To make things a little less confusing, we’re here with all the info you need about popular weight loss med Mounjaro.

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an increased risk of rare eye conditions.

One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition ...

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...

The FDA said it's taking action to protect patients from unapproved animal-derived thyroid medications and expressed concern ...

The lawsuit, which was filed in U.S. District Court in New Jersey by a single investor, Eric Barta, is a class action on ...